July 15, 2024
National Institute on Drug Abuse (NIDA)
This notice is to clarify the integration of substance use and HIV research in the research projects submitted for NIDAs Directors Pioneer Series Awards including PAR-23-269: NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) and PAR-23-125: Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional).
The Avant Garde and Avenir programs invite research grant applications addressing high priority HIV research areas for the National Institute on Drug Abuse (NIDA) and the NIH (as stated in the NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding).
The NIDA HIV research program supports research at the intersection of substance use, HIV, and related comorbidities that generates evidence-based strategies to improve individual and public health. Listed below are the NIDAs HIV research priorities.
NIDA developed the DP1 PAR-23-269 and DP2 PAR-23-125 funding opportunities to accelerate scientific discoveries at the intersection of HIV and substance use research. Both these funding opportunities require the applicants to clearly define the nexus with substance use in their HIV research projects. Examples of relevant studies include research using populations and/or samples from people with substance use disorder (SUD); studies using in vitro systems and/or animal models that test the effects of addictive substances on HIV pathogenesis, disease progression, persistence or treatment responses; and studies to develop interventions or treatments that are tailored to people with SUD.
We hereby provide additional guidance on consideration of substance use in the Avant-Garde (DP1) and Avenir (DP2) research projects. NIDA requires these DP1 and DP2 HIV research projects to explain ‘how and ‘why substance use is considered in the research project by either addressing aspects of substance use in research and analysis as applicable in the individual research projects or by making clear the implications of the research for people using drugs or with a SUD. The research plan must clearly explain:
Please direct all inquiries to:
Scientific/Research Contact(s)
Redonna Chandler, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1919
Email: redonna.chandler@nida.nih.gov
Vasundhara Varthakavi, DVM, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov
Peer Review Contact(s)
Dharmendar Rathore, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-6965
Email: dharmendar.rathore@nih.gov
Financial/Grants Management Contact(s)
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@nih.gov